Compare Match Group Inc (MTCH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.2× Match Group Inc's market cap, and Match Group Inc pays a 1.94% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MTCH | VRTX | |
|---|---|---|
Market Cap | $9.45B | $134.06B |
Sector | Media | Health |
52-Week High | $42.44 | $557.96 |
52-Week Low | $28.90 | $376.62 |
Enterprise Value | $12.41B | $128.18B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near the analyst low target of $41.00. The stock shows a bullish technical trend with recent earnings beating expectations in Q2 2026. Fundamentals are solid with a P/E of 14.59, net income margin of 20.17%, and strong cash flow growth. Recent news highlights AI-driven product innovations at Tinder and institutional buying interest.
Outlook is positive with a consensus price target of $42.50, offering modest upside. Key opportunities include AI integration and user growth, while risks involve high debt levels and competitive pressures in the dating app market. The stock presents a balanced risk-reward profile for growth-oriented investors.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
